Evidence map›Paper›PMID 42262686›Full record

ArticleInternational journal of clinical oncology2026

A multicenter survey on BRAF screening for the implementation of perioperative cancer genomic medicine for resectable colorectal oligometastases.

Shin Kobayashi, Nobuhisa Matsuhashi, Yusuke Suwa, Tetsuro Kawazoe, Akira Ouchi, Manabu Shiozawa, Akio Shiomi, Mitsuru Yokota, Eiji Shinozaki, Yasuyuki Takamizawa and 10 more

Abstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in International journal of clinical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Shin KobayashiDepartment of Hepatobiliary and Pancreatic Surgery, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, Chiba, 2770882, Japan. shkobaya@east.ncc.go.jp.ORCID http://orcid.org/0000-0001-9321-8452
Nobuhisa MatsuhashiDepartment of Gastroenterological Surgery, Pediatric Surgery, Gifu University Hospital, Gifu, Japan.
Yusuke SuwaDepartment of Surgery, Gastroenterological Center, Yokohama City University Medical Center, Yokohama, Japan.
Tetsuro KawazoeDepartment of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Akira OuchiDepartment of Gastroenterological Surgery, Aichi Cancer Center Hospital, Nagoya, Japan.
Manabu ShiozawaDepartment of Gastrointestinal Surgery, Kanagawa Cancer Center, Yokohama, Japan.
Akio ShiomiDivision of Colon and Rectal Surgery, Shizuoka Cancer Center, Shizuoka, Japan.
Mitsuru YokotaDepartment of General Surgery, Kurashiki Central Hospital, Kurashiki, Japan.
Eiji ShinozakiGastrointestinal Oncology Department, The Cancer Institute Hospital of JFCR, Tokyo, Japan.
Yasuyuki TakamizawaDepartment of Colorectal Surgery, National Cancer Center Hospital, Tokyo, Japan.
Yujiro NishizawaDepartment of Gastroenterological Surgery, Osaka General Medical Center, Osaka, Japan.
Yukiharu HiyoshiDepartment of Gastroenterological Surgery, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan.
Tatsuhiko KakisakaDepartment of Gastroenterological Surgery I, Hokkaido University Graduate School of Medicine, Sapporo, Japan.
Shinobu OhnumaDepartment of Surgery, Tohoku University Graduate School of Medicine, Sendai, Japan.
Toshiro OguraDepartment of Gastroenterological Surgery, Saitama Cancer Center, Ina, Japan.
Hiroko HasegawaDepartment of Gastroenterology and Hepatology, NHO Osaka National Hospital, Osaka, Japan.
Masahito KotakaGastrointestinal Cancer Center, Sano Hospital, Kobe, Japan.
Keiji HirataDepartment of Surgery 1, University of Occupational and Environmental Health, Kitakyushu, Japan.
Hideaki BandoDepartment of Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
Takayuki YoshinoDepartment of Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan.

Funding

Japan Agency for Medical Research and Development 25lk0221211h0001National Cancer Center 2024-A-05
6 · The paper itself

Abstract

backgroundGenomic screening is an essential, but potentially time-consuming procedure, especially in neoadjuvant settings. We evaluated the preoperative screening of the BRAF V600E mutation for recruitment to a clinical trial among patients with resectable colorectal oligometastases (CRM).

methodsIn April 2022, an investigator-initiated trial was launched to investigate the efficacy and safety of perioperative use of the BEACON triplet regimen for BRAF V600E mutant resectable CRM. BRAF screening was retrospectively conducted in patients with resected colorectal liver metastases in 2019 for planning the trial and prospectively conducted in preoperative patients with resectable CRM from January 2022 to June 2025 for patient recruitment to the trial.

resultsBRAF V600E mutation was detected in 12 (3.2%) of 379 postoperative patients retrospectively and in 36 (1.7%) of 2140 preoperative patients prospectively, with 1840 patients (86.0%) carrying the wild-type and 264 patients (12.3%) classified as untested. The detection rate of the BRAF V600E mutation was significantly lower when the screening was performed prospectively in preoperative patients (P < 0.001). The untested rates varied across metastatic organs, with 10.3% in the liver, 18.1% in the lungs, 12.0% in the lymph nodes, 16.7% in the peritoneum, and 7.8% in other organs. The untested rates decreased consistently across semiannual comparisons: 28.5% in the first evaluation, followed by 15.0%, 12.0%, 8.4%, 9.1%, 7.3%, and 7.1% (P < 0.01 when compared with the first period).

conclusionRaising physician awareness, as reflected by the untested rate, is a crucial factor in conducting clinical trials to implement perioperative cancer genomic medicine.

Indexed as

Colorectal NeoplasmsLiver NeoplasmsProto-Oncogene Proteins B-rafAdultAgedFemaleGenomicsHumansMaleMiddle AgedMutationProspective StudiesRetrospective StudiesBRAF protein, humanProto-Oncogene Proteins B-rafBRAF V600EColorectal cancerGenomic medicineOligometastasesResectableScreening

Identifiers

PMID42262686

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.